What does the Onpattro (patisiran) label include?
The Onpattro label is the package insert approved by regulators for patients and clinicians. It summarizes what the medicine is for, how it should be used, and the key safety information.
Onpattro (patisiran) is indicated for certain people with hereditary transthyretin (hATTR) amyloidosis:
- It is used for adults with hATTR amyloidosis who have polyneuropathy.
- The label includes specific eligibility details based on subtype (hereditary) and stage/severity of polyneuropathy.
The label also covers how Onpattro is administered (including infusion-related instructions) and the monitoring and precautions needed to reduce risks associated with treatment.
How is Onpattro given according to the label?
The label specifies dosing and administration requirements for Onpattro, including that it is given as an IV infusion. It also includes precautions around infusion reactions and related premedication/monitoring instructions that clinicians must follow when administering the drug.
What safety warnings are on the Onpattro label?
The Onpattro label includes warnings and safety information focused on:
- Infusion-related reactions and hypersensitivity risk, with guidance on what to monitor during administration.
- Other clinically important adverse reactions and lab/clinical monitoring requirements described in the prescribing information.
What do patients usually look for on the Onpattro label?
Common label items patients search for include:
- Who can take it (indication and eligibility)
- Dosing schedule
- Common and serious side effects
- Infusion precautions (what happens during treatment and what premedication is used)
- Monitoring guidance (what clinicians check over time)
If you want, paste the exact Onpattro label text you’re looking at (or tell me whether you mean the FDA label in the US or another country’s labeling). I can then extract the specific section you need, such as “Indications and Usage,” “Dosage and Administration,” or “Warnings and Precautions.”